Castle Biosciences raises 2026 revenue guidance to $365M-$375M as TissueCypher volume trends toward 50%-52% growth
Castle Biosciences has raised its 2026 revenue guidance from $365 million to $375 million, driven by the growth of TissueCypher.
The recent news of a strong upward revision in revenue guidance, along with the recent stock price trend, is very positive. On July 30, there was already a significant increase, and today (July 31), the opening price is forming high, indicating continued upward momentum, which prompts consideration for entry.
If the stock price reaches $30.0, I will take profits, and if it falls below $24.5, I will cut losses.
The forecasted return was 4.5%, but the actual return was 12.9%, significantly exceeding the forecast. While the direction of the stock price increase due to positive news was accurately predicted, it was confirmed that the strength of the increase was much stronger than expected.
We recognize that the price volatility may be greater than expected in the event of positive developments, and we will enhance our response strategy when the trend is strongly established.